Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Severe dapsone hypersensitivity syndrome in a child

  • Choi, So Yoon (Department of Pediatrics, Kosin University Gospel Hospital) ;
  • Hwang, Ho Yeon (Department of Pediatrics, Kosin University Gospel Hospital) ;
  • Lee, Jung Hyun (Department of Pediatrics, Kosin University Gospel Hospital) ;
  • Park, Jae Sun (Department of Pediatrics, Kosin University Gospel Hospital) ;
  • Jang, Min Soo (Department of Dermatology, Kosin University Gospel Hospital)
  • 투고 : 2012.08.31
  • 심사 : 2012.10.25
  • 발행 : 2013.06.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Dapsone (4,4'-diaminodiphenylsulfone, DDS), a potent anti-inflammatory agent, is widely used in the treatment of leprosy and several chronic inflammatory skin diseases. Dapsone therapy rarely results in development of dapsone hypersensitivity syndrome, which is characterized by fever, hepatitis, generalized exfoliative dermatitis, and lymphadenopathy. Here, we describe the case of an 11-year-old Korean boy who initially presented with high fever, a morbilliform skin rash, generalized lymphadenopathy, hepatosplenomegaly, and leukopenia after 6 weeks of dapsone intake. Subsequently, he exhibited cholecystitis, gingivitis, colitis, sepsis, aseptic meningitis, disseminated intravascular coagulation, syndrome of inappropriate antidiuretic hormone secretion, pneumonia, pleural effusions, peritonitis, bronchiectatic changes, exfoliative dermatitis, and acute renal failure. After 2 months of supportive therapy, and prednisolone and antibiotic administration, most of the systemic symptoms resolved, with the exception of exfoliative dermatitis and erythema, which ameliorated over the following 4 months. Agranulocytosis, atypical lymphocytosis, aseptic meningitis, and bronchiectatic changes along with prolonged systemic symptoms with exfoliative dermatitis were the most peculiar features of the present case.

키워드

참고문헌

  1. Ben m'rad M, Leclerc-Mercier S, Blanche P, Franck N, Rozenberg F, Fulla Y, et al. Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients. Medicine (Baltimore) 2009;88:131-40. https://doi.org/10.1097/MD.0b013e3181a4d1a1
  2. Seoh JK, Bae HK, Yang JS, Choi ED, Lim BK, Kim JS. A case of dapsone syndrome. J Korean Pediatr Soc 1988;31:1376-80.
  3. Won YJ, Kim OL, Yu ST, Yoon YW, Choi DY. A case of dapsone syndrome. Korean J Pediatr 2007;50:493-6. https://doi.org/10.3345/kjp.2007.50.5.493
  4. Kim GW, Park HJ, Kim HS, Kim SH, Ko HC, Kim BS, et al. Dapsone hypersensitivity syndrome that occurred during treatment of pediatric patient with erythema elevatum diutinum. Ann Dermatol 2011;23(Suppl 3):S290-5. https://doi.org/10.5021/ad.2011.23.S3.S290
  5. Lorenz M, Wozel G, Schmitt J. Hypersensitivity reactions to dapsone: a systematic review. Acta Derm Venereol 2012;92:194-9. https://doi.org/10.2340/00015555-1268
  6. Sago J, Hall III RP. Dapsone. Dermatol Ther 2002;15:340-51. https://doi.org/10.1046/j.1529-8019.2002.01543.x
  7. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol 2001;45:420-34. https://doi.org/10.1067/mjd.2001.114733
  8. Sener O, Doganci L, Safali M, Besirbellioglu B, Bulucu F, Pahsa A. Severe dapsone hypersensitivity syndrome. J Investig Allergol Clin Immunol 2006;16:268-70.
  9. Lee CH, Jang SJ, Oh SR, Kim HJ, Lee MS. A case of fatal DRESS syndrome caused by dapsone in a patient with Behcet's syndrome. J Korean Rheum Assoc 2009;16:253-7. https://doi.org/10.4078/jkra.2009.16.3.253
  10. Zhou JG, Cai SQ, Zheng M. Dapsone-induced infectious mononucleosis-like syndrome in a patient with pemphigus vulgaris. Chin Med J (Engl) 2007;120:1111-3.
  11. Prussick R, Shear NH. Dapsone hypersensitivity syndrome. J Am Acad Dermatol 1996;35(2 Pt 2):346-9. https://doi.org/10.1016/S0190-9622(96)90667-2
  12. Gill HJ, Tingle MD, Park BK. N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Br J Clin Pharmacol 1995;40:531-8. https://doi.org/10.1111/j.1365-2125.1995.tb05797.x
  13. Rieder MJ, Uetrecht J, Shear NH, Cannon M, Miller M, Spielberg SP. Diagnosis of sulfonamide hypersensitivity reactions by in-vitro "rechallenge" with hydroxylamine metabolites. Ann Intern Med 1989;110:286-9. https://doi.org/10.7326/0003-4819-110-4-286
  14. Lupton GP, Odom RB. The allopurinol hypersensitivity syndrome. J Am Acad Dermatol 1979;1:365-74.
  15. Ang CC, Wang YS, Yoosuff EL, Tay YK. Retrospective analysis of drug-induced hypersensitivity syndrome: a study of 27 patients. J Am Acad Dermatol 2010;63:219-27. https://doi.org/10.1016/j.jaad.2009.08.050
  16. Capra C, Monza GM, Meazza G, Ramella G. Trimethoprim-sulfamethoxazole-induced aseptic meningitis: case report and literature review. Intensive Care Med 2000;26:212-4. https://doi.org/10.1007/s001340050048
  17. Carrillo F, Cubero A, Hernandez Gallego J, Jimenez Santana P. Recurrence of meningoencephalitis induced by cotrimoxazole. Rev Neurol 1995;23:142-4.
  18. Moris G, Garcia-Monco JC. The challenge of drug-induced aseptic meningitis. Arch Intern Med 1999;159:1185-94. https://doi.org/10.1001/archinte.159.11.1185
  19. Lee RZ, Hardiman O, O'Connell PG. Ibuprofen-induced aseptic meningoencephalitis. Rheumatology (Oxford) 2002;41:353-5. https://doi.org/10.1093/rheumatology/41.3.353
  20. Tobin-D'Angelo MJ, Hoteit MA, Brown KV, Ray SM, King MD. Dapsone-induced hypersensitivity pneumonitis mimicking Pneumocystis carinii pneumonia in a patient with AIDS. Am J Med Sci 2004;327:163-5. https://doi.org/10.1097/00000441-200403000-00010

피인용 문헌

  1. Dapsone : Dapsone hypersensitivity syndrome in a child: case report vol.1462, pp.1, 2013, https://doi.org/10.1007/s40278-013-4734-x
  2. Dapsone Hypersensitivity Syndrome (DHS): A Detrimental Effect of Dapsone? A Case Report vol.14, pp.1, 2013, https://doi.org/10.2174/1574886313666180731123232
  3. Drug reaction with eosinophilia and systemic symptoms (DRESS) in the pediatric population: A systematic review of the literature vol.83, pp.5, 2013, https://doi.org/10.1016/j.jaad.2020.03.081